NEWS | alsv | Page 4 of 15

Companies in the News

Sana snags $587.5M IPO to catapult cell therapies into the clinic

Massive private raise? Check. Preclinical pipeline? Check. Now, Sana Biotechnology is raising $587.5 million in a mammoth IPO that will...

Gilead Sciences and Gritstone Announce Collaboration For HIV Cure

FOSTER CITY, Calif. and EMERYVILLE, Calif., Feb. 01, 2021 (GLOBE NEWSWIRE) -- Gilead Sciences, Inc. (Nasdaq: GILD) and Gritstone...

Gritstone Advances Second Generation COVID-19 Vaccine “CORAL” Program with Support from NIAID

EMERYVILLE, Calif., Jan. 19, 2021 (GLOBE NEWSWIRE) -- Gritstone Oncology, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company...

Tessera Therapeutics Attracts Over $230M in Series B Financing to Advance ‘Gene Writing’

SoftBank Vision Fund 2, Alaska Permanent Fund Corporation, Altitude Life Science Ventures, Qatar Investment Authority, and Other New...

Top Life Sciences Startups to Watch in 2021

BioSpace is proud to present its NextGen Bio “Class of 2021,” a list of up-and-coming life sciences companies in North America that...

Beam Therapeutics Presents Updated Data from Novel Base Editing Programs for Sickle Cell Disease

BEAM-101 Data Highlight Precision of Base Editor with No Off-Target Editing Observed; Will Support Planned IND Submission in the Second...

Gritstone Oncology Advances into Phase 2 Expansion Cohorts for its Personalized Neoantigen Therapy

EMERYVILLE, Calif., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Gritstone Oncology Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company...

eFFECTOR’s Zotatifin (eFT226) Downregulates Key Oncogenic Driver Proteins Including RTKs

SAN DIEGO, Oct. 26, 2020 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc., a leader in the development of selective translation regulation...

Nuvation Bio and Panacea Announce Business Combination Agreement, Creating a Public Oncology Leader

Leading institutional investors commit $500 million through concurrent equity investments Upon completion of the business combination,...